The journal of prevention of Alzheimer's disease · 2025
Liver function and Alzheimer's brain pathologies: A longitudinal study: Liver and Alzheimer's pathologies.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Jee Wook, Byun Min Soo, Yi Dahyun, Jung Joon Hyung, Kong Nayeong, Chang Yoon Young, Jung Gijung, Ahn Hyejin, Lee Jun-Young, Kang Koung Mi, Sohn Chul-Ho, Lee Yun-Sang, Kim Yu Kyeong, Lee Dong Young, KBASE Research Group
Аннотация
IMPORTANCE: The neuropathological links underlying the association between changes in liver function and AD have not yet been clearly elucidated.
OBJECTIVE: We aimed to examine the relationship between liver function markers and longitudinal changes in Alzheimer's disease (AD) core pathologies.
DESIGN: Data from the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease, a longitudinal cohort study initiated in 2014, were utilized.
SETTING: Community and memory clinic setting.
PARTICIPANTS: Three hundred forty-seven older adults.
MAIN OUTCOME AND MEASURES: Participants underwent baseline and 2-year follow-up evaluations, including liver function assessments and various brain imaging techniques, such as amyloid and tau PET, FDG-PET, and MRI). Liver function indicators [alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin] were examined as exposure variables.
RESULTS: Higher baseline ALT levels were associated with a greater increase in beta-amyloid deposition over 2 years [β = 0.166, Bonferroni-corrected P (PB) = 0.012], while lower total bilirubin levels were associated with a greater increase in tau deposition over the same period (β = -0.570, PB < 0.001). In contrast, AST alone showed no significant association with changes of AD pathologies.
CONCLUSIONS AND RELEVANCE: The findings suggest a possible link between lower liver function and the accumulation of core AD pathologies in the brain. These results also support the possibility that the liver-brain axis could be a potential target for therapeutic or preventive strategies against AD.
OBJECTIVE: We aimed to examine the relationship between liver function markers and longitudinal changes in Alzheimer's disease (AD) core pathologies.
DESIGN: Data from the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease, a longitudinal cohort study initiated in 2014, were utilized.
SETTING: Community and memory clinic setting.
PARTICIPANTS: Three hundred forty-seven older adults.
MAIN OUTCOME AND MEASURES: Participants underwent baseline and 2-year follow-up evaluations, including liver function assessments and various brain imaging techniques, such as amyloid and tau PET, FDG-PET, and MRI). Liver function indicators [alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin] were examined as exposure variables.
RESULTS: Higher baseline ALT levels were associated with a greater increase in beta-amyloid deposition over 2 years [β = 0.166, Bonferroni-corrected P (PB) = 0.012], while lower total bilirubin levels were associated with a greater increase in tau deposition over the same period (β = -0.570, PB < 0.001). In contrast, AST alone showed no significant association with changes of AD pathologies.
CONCLUSIONS AND RELEVANCE: The findings suggest a possible link between lower liver function and the accumulation of core AD pathologies in the brain. These results also support the possibility that the liver-brain axis could be a potential target for therapeutic or preventive strategies against AD.